Gut microbiota-related complications in cirrhosis.
Gut microbiota plays an important role in cirrhosis. The liver is constantly challenged with commensal bacteria and their products arriving through the portal vein in the so-called gut-liver axis. Bacterial translocation from the intestinal lumen through the intestinal wall and to mesenteric lymph nodes is facilitated by intestinal bacterial overgrowth, impairment in the permeability of the intestinal mucosal barrier, and deficiencies in local host immune defences. Deranged clearance of endogenous bacteria from portal and systemic circulation turns the gut into the major source of bacterial-related complications. Liver function may therefore be affected by alterations in the composition of the intestinal microbiota and a role for commensal flora has been evidenced in the pathogenesis of several complications arising in end-stage liver disease such as hepatic encephalopathy, splanchnic arterial vasodilatation and spontaneous bacterial peritonitis. The use of antibiotics is the main therapeutic pipeline in the management of these bacteria-related complications. However, other strategies aimed at preserving intestinal homeostasis through the use of pre-, pro- or symbiotic formulations are being studied in the last years. In this review, the role of intestinal microbiota in the development of the most frequent complications arising in cirrhosis and the different clinical and experimental studies conducted to prevent or improve these complications by modifying the gut microbiota composition are summarized.
Isabel Gómez-Hurtado, José Such, Rubén Francés, CIBERehd-Liver Unit, Hospital General Universitario Alicante, Alicante 03010, Spain.
Isabel
I
Gómez-Hurtado
Isabel Gómez-Hurtado, José Such, Rubén Francés, CIBERehd-Liver Unit, Hospital General Universitario Alicante, Alicante 03010, Spain.
José
J
Such
Isabel Gómez-Hurtado, José Such, Rubén Francés, CIBERehd-Liver Unit, Hospital General Universitario Alicante, Alicante 03010, Spain.
Yolanda
Y
Sanz
Isabel Gómez-Hurtado, José Such, Rubén Francés, CIBERehd-Liver Unit, Hospital General Universitario Alicante, Alicante 03010, Spain.
Rubén
R
Francés
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018988:Bacterial Translocation; D004932:Esophageal and Gastric Varices / Q000382:microbiology; D006501:Hepatic Encephalopathy / Q000382:microbiology / Q000523:psychology; D054884:Host-Pathogen Interactions; D006801:Humans; D006975:Hypertension, Portal / Q000382:microbiology / Q000503:physiopathology; D007422:Intestines / Q000187:drug effects / Q000382:microbiology* / Q000503:physiopathology; D008099:Liver / Q000187:drug effects / Q000382:microbiology* / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000503:physiopathology; D064307:Microbiota / Q000187:drug effects; D010538:Peritonitis / Q000382:microbiology; D011379:Prognosis; D013152:Splanchnic Circulation; D014664:Vasodilation
D000900:Anti-Bacterial Agents
Bacterial translocation; Cirrhosis; Encephalopathy; Microbiota; Portal hypertension; Spontaneous bacterial peritonitis